The actual device was discarded by the facility.Therefore the investigation was limited to the user facility information, quality records, and a retention sample from the involved product code/lot# combination.Visual inspection of the retention sample found no anomalies in the appearance.The device was circulated with bovine blood at the flow rate of 500ml/min by using a roller pump.Blood was confirmed to run through it with no difficulty.Bovine blood was circulated through the device while ultra-filtrating performance and the pressure drop was determined.The obtained value was confirmed to meet manufacturing specification.A review of the device history record and shipping inspection record of the involved product code/lot number combination was conducted with no relevant findings.A search of the complaint file found no other report with the involved product code/lot# combination.The investigation results verified that the retention sample was normal product.Based on the available information, the cause for the reported event cannot be definitively determined.There are many complex clinical variables that may have affected the reportedly observed conditions during the procedure.However, there is no indication that the reported event was related to a product defect or malfunction.The device labeling does address the potential for such an occurrence in the instruction for use (ifu) with the statement such as the following: the capiox hemoconcentrator is designed to operate at flow rates within the range of 100 to 500 ml/min during ultrafiltration.Do not use blood flow rates outside this range.Less than 100ml/min blood flow may cause blood coagulation in the device.Stop using the hemoconcentrator if blood leakage, clotting or any other problem is observed.Replace it with a new one." (b)(4).All available information has been placed on file in quality assurance at the manufacturing facility for appropriate tracking, trending and follow-up.Sample discarded.
|